JPRN-jRCT2080221099未知1 期
Phase I, Multiple Dose Study of MLN0002 in Patients with Ulcerative Colitis
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 70age old（—）
- 性别
- All
入选标准
- •1)Patients with well-defined ulcerative colitis
- •2)Patients who agree to use routinely adequate contraception
- •3)Patients weigh at least 40 kg
排除标准
- •1)Patients for whom surgical intervention for their ulcerative colitis is currently required or anticipated
- •2)Patients with dysplasia or cancer of colon or rectum
- •3)Patients with symptoms of intestinal stenosis, history of intestinal resection (except for appendectomy)
- •4)Patients with intestinal diseases other than ulcerative colitis (radiation colitis, ischemic colitis, drug-induced colitis, Crohn's disease, intestinal Behcet disease, lymphoid follicular hyperplasia, etc.)
- •5)Patients with presence or history of active or latent tuberculosis
- •6)Female patients who are pregnant or lactating
- •7)Patients with prior exposure to MLN0002, natalizumab, rituximab, or efalizumab
研究者
相似试验
未知
1 期
MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase CAdvanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction AdenocarcinomaJPRN-jRCT2080222799TAKEDA PHARMACEUTICAL COMPANY LTD.95
进行中（未招募）
不适用
A trial to evaluate MLN0264 for the treatment of tumors of the stomach or the junction between the esophagus and the stomach and which have a protein called Guanylyl Cyclase C (GCC) present, in patients that have been treated previously but who have relapsed or in whom the cancer has spread.Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)MedDRA version: 17.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10001158Term: Adenocarcinoma gastric stage IV with metastasesSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10001152Term: Adenocarcinoma gastric recurrentSystem Organ Class: 100000004864EUCTR2014-000804-88-ITMillennium Pharmaceuticals, Inc.81
进行中（未招募）
不适用
A trial to evaluate MLN0264 for the treatment of tumors of the stomach or the junction between the esophagus and the stomach and which have a protein called Guanylyl Cyclase C (GCC) present, in patients that have been treated previously but who have relapsed or in whom the cancer has spread.Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)MedDRA version: 17.0Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10001158Term: Adenocarcinoma gastric stage IV with metastasesSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10001152Term: Adenocarcinoma gastric recurrentSystem Organ Class: 100000004864EUCTR2014-000804-88-ESMillennium Pharmaceuticals, Inc.81
进行中（未招募）
1 期
A trial to evaluate MLN0264 for the treatment of pancreatic tumors which have a protein called Guanylyl Cyclase C (GCC) present, in patients that have been treated previously and in whom the cancer is advanced or has spread.EUCTR2014-000805-11-GBMillennium Pharmaceuticals, Inc.81
进行中（未招募）
不适用
A trial to evaluate MLN0264 for the treatment of tumors of the stomach or the junction between the esophagus and the stomach and which have a protein called Guanylyl Cyclase C (GCC) present, in patients that have been treated previously but who have relapsed or in whom the cancer has spread.EUCTR2014-000804-88-BEMillennium Pharmaceuticals, Inc.81